INEX files response, counterclaim against Protiva in Biotherapeutics siRNA dispute

By Lisa Kerner

Erie, Pa., May 1 - INEX Pharmaceuticals Corp., its directors and officers filed statements of defense in response to a claim filed by Protiva Biotherapeutics Inc. in the Supreme Court of British Columbia.

The company also filed a counterclaim against Protiva.

INEX's dispute with Protiva, spun-out from INEX in 2001, is over the rights to certain drug delivery technology for oligonucleotides, including small interfering RNA (siRNA).

As part of the 2001 agreements that formed Protiva, INEX retained all rights to the delivery of oligonucleotides, including siRNA, according to a news release.

INEX said it believes that any technology advancements made by Protiva and its collaborators or by INEX for the delivery of oligonucleotides, including siRNA, are either owned by INEX or should be licensed to INEX.

The company is developing oligonucleotide drugs for a number of different applications and recently signed a research collaboration with Alnylam Pharmaceuticals Inc., combining INEX's expertise in the systemic delivery of oligonucleotides and Alnylam's expertise in RNAi therapeutics and siRNA.

INEX, based in Vancouver, B.C., develops and commercializes proprietary drugs and drug delivery systems for the treatment.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.